Hioki C, Yoshida T, Kogure A, Takakura Y, Umekawa T, Yoshioka K, Shimatsu A, Yoshikawa T
Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Japan.
Horm Metab Res. 2004 Sep;36(9):607-13. doi: 10.1055/s-2004-825905.
We have investigated whether GH treatment influences the expression of UCP1, 2 and 3 mRNA in a KK-Ay obese mouse model. KK-Ay mice (n = 10) and C57Bl/6J control mice (n = 10) were injected subcutaneously with human GH (1.0 mg/kg/day and 3.5 mg/kg/day) for 10 days, and compared with mice injected with physical saline. The KK-Ay obese mice weighed significantly less (p < 0.01 : 1.0 mg/kg/day, p < 0.05 : 3.5 mg/kg/day) and had smaller inguinal subcutaneous and perimetric white adipose tissue (WAT) pads (p < 0.05 : 3.5 mg/kg/day), but increased skeletal muscle weight (p < 0.05). The brown adipose tissue (BAT) weight did not change significantly. Not only plasma free fatty acid and glucose levels but also plasma insulin levels decreased. The reduced HOMA-IR (homeostasis model assessment-insulin resistance) values suggested that insulin resistance was improved by GH treatment. UCP1 mRNA levels increased after the 3.5 mg GH treatment by 2.8-fold (p < 0.01 vs. saline controls) and 2.0-fold (p < 0.05 vs. 1 mg GH treatment) in BAT, and by 6.0-fold in subcutaneous WAT (p < 0.05 vs. controls). UCP2 mRNA levels increased 2.2-fold (p < 0.05 vs. control) and 2.1-fold (p < 0.05 vs. 1 mg GH treatment) in BAT, and 2.0-fold (p < 0.05 vs. controls) in skeletal muscle. One mg GH administration also stimulated UCP1 mRNA expression by 2.5-fold (p < 0.05 vs. controls) and UCP3 mRNA expression by 2.8-fold (p < 0.05 vs. controls) in the muscle. On the other hand, lean mice showed no significant difference in body composition or plasma parameters. UCP1, 2 and 3 mRNA expression in lean mice did not show any significant change after treatment with GH. We conclude that GH treatment increased mRNA levels for not only UCP1, but also UCP 2 and 3 in BAT, WAT and muscle in a KK-Ay obese mouse model. These findings suggest that GH-induced thermogenesis may contribute to the reduction in WAT and energy expenditure.
我们研究了生长激素(GH)治疗是否会影响KK-Ay肥胖小鼠模型中解偶联蛋白1(UCP1)、解偶联蛋白2(UCP2)和解偶联蛋白3(UCP3)mRNA的表达。将KK-Ay小鼠(n = 10)和C57Bl/6J对照小鼠(n = 10)皮下注射人GH(1.0mg/kg/天和3.5mg/kg/天),持续10天,并与注射生理盐水的小鼠进行比较。KK-Ay肥胖小鼠体重显著减轻(p < 0.01:1.0mg/kg/天,p < 0.05:3.5mg/kg/天),腹股沟皮下和周边白色脂肪组织(WAT)垫较小(p < 0.05:3.5mg/kg/天),但骨骼肌重量增加(p < 0.05)。棕色脂肪组织(BAT)重量无显著变化。血浆游离脂肪酸、葡萄糖水平以及血浆胰岛素水平均降低。稳态模型评估胰岛素抵抗(HOMA-IR)值降低表明GH治疗改善了胰岛素抵抗。3.5mg GH治疗后,BAT中UCP1 mRNA水平增加2.8倍(与生理盐水对照组相比,p < 0.01)和2.0倍(与1mg GH治疗组相比,p < 0.05),皮下WAT中增加6.0倍(与对照组相比,p < 0.05)。BAT中UCP2 mRNA水平增加2.2倍(与对照组相比,p < 0.05)和2.1倍(与1mg GH治疗组相比,p < 0.05),骨骼肌中增加2.0倍(与对照组相比,p < 0.05)。给予1mg GH也刺激了肌肉中UCP1 mRNA表达增加2.5倍(与对照组相比,p < 0.05)和UCP3 mRNA表达增加2.8倍(与对照组相比,p < 0.05)。另一方面,瘦小鼠在身体组成或血浆参数方面无显著差异。GH治疗后,瘦小鼠中UCP1、UCP2和UCP3 mRNA表达未显示任何显著变化。我们得出结论,在KK-Ay肥胖小鼠模型中,GH治疗不仅增加了BAT、WAT和肌肉中UCP1的mRNA水平,还增加了UCP2和UCP3的mRNA水平。这些发现表明,GH诱导的产热可能有助于减少WAT和能量消耗。